Quick Read
- Daraxonrasib nearly doubled median survival time to 13.2 months compared to 6.7 months with chemotherapy.
- The drug targets RAS mutations, a genetic driver found in 90% of pancreatic cancer cases.
- Revolution Medicines plans to seek expedited FDA approval using a National Priority Voucher.
Medical researchers have reached a potential turning point in the treatment of pancreatic cancer, as new Phase 3 trial data released on April 13, 2026, confirms that the oral drug daraxonrasib significantly extends survival rates for patients with advanced disease. Developed by Revolution Medicines, the daily pill demonstrated the ability to nearly double the survival time compared to traditional chemotherapy, marking what clinicians are calling an unprecedented advancement for one of the most aggressive forms of cancer.
Targeting RAS Mutations for Superior Outcomes
Pancreatic cancer has historically remained one of the most difficult malignancies to treat, characterized by a five-year survival rate of approximately 13%. The disease is driven in roughly 90% of cases by specific RAS mutations, which have long been considered “undruggable.” Daraxonrasib works by targeting these mutations directly. In the recent trial, patients treated with the drug experienced a median survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy, representing a 60% reduction in the risk of death.
Clinical Impact and Patient Perspectives
The medical community has reacted with cautious optimism, noting that while side effects such as facial rashes are common, they are generally manageable through clinical intervention. Dr. Shubham Pant, a professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, described the results as transformational. The urgency of these findings has been highlighted by high-profile patients, including former U.S. Senator Ben Sasse, who has been treated with the drug as part of a clinical trial. His experience underscores the shift from palliative care to aggressive, targeted therapy as a viable path forward.
Accelerating Access to New Therapies
Following the successful trial, Revolution Medicines has announced plans to seek rapid approval from the U.S. Food and Drug Administration (FDA) utilizing a National Priority Voucher, which could expedite the review process to a matter of months. As the company prepares for a potential rollout, experts like Dr. Andrew Aguirre of the Dana-Farber Cancer Institute suggest that daraxonrasib could serve as a foundational therapy, eventually being used in combination with other agents to further improve patient outcomes. The data represents a foundational shift in oncology, moving the field away from exclusively cytotoxic chemotherapy toward targeted molecular therapies that address the specific genetic drivers of tumor growth, potentially setting a new benchmark for future clinical trials in high-mortality cancers.